Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Rhea-AI Summary

Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced the schedule for its second quarter 2024 financial results and corporate update. The company will release its Q2 2024 press release on Thursday, August 1, 2024, at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET on the same day.

Interested parties can register for the conference call using the provided link. Additionally, a live webcast of the conference call will be accessible through the Investors section of Arbutus' website, with an archived version available after the event.

WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its second quarter 2024 financial results and corporate update for Thursday, August 1, 2024. The schedule for the press release and conference call/webcast are as follows:

•	Q2 2024 Press Release:	Thursday, August 1, 2024 at 7:30 a.m. ET
•	Q2 2024 Conference Call/Webcast:	Thursday, August 1, 2024 at 8:45 a.m. ET

To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

When will Arbutus Biopharma (ABUS) report its Q2 2024 financial results?

Arbutus Biopharma (ABUS) will report its Q2 2024 financial results on Thursday, August 1, 2024. The press release will be issued at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET.

How can I access Arbutus Biopharma's (ABUS) Q2 2024 earnings call?

You can access Arbutus Biopharma's (ABUS) Q2 2024 earnings call by registering through the provided link for the conference call. Additionally, a live webcast will be available through the Investors section of Arbutus' website at www.arbutusbio.com.

What is the main focus of Arbutus Biopharma (ABUS)?

Arbutus Biopharma (ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection.